Davoudi Ehsan Taghizadeh, bin-Noordin Mohamed Ibrahim, Javar Hamid Akbari, Kadivar Ali, Sabeti Bahare
Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia/Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of medical sciences, Tehran, Iran.
Pak J Pharm Sci. 2014 Jan;27(1):203-8.
Cancer is among most important causes of death in recent decades. Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments. The purpose of this work is to provide an overview and also deeper insight to renal cell carcinoma and the steps which have been taken to reach more specific treatment and target therapy, in this type of cancer by developing most effective agents such as Sorafenib. To achieve this goal hundreds of research paper and published work has been overviewed and due to limitation of space in a paper just focus in most important points on renal cell carcinoma, treatment of RCC and clinical development of Sorafenib. The information presented this paper shows the advanced of human knowledge to provide more efficient drug in treatment of some complicated cancer such as RCC in promising much better future to fight killing disease.
癌症是近几十年来最重要的死因之一。肾细胞癌的发病率较低，但就病理生理学和治疗而言，它似乎比其他癌症更为复杂。这项工作的目的是概述肾细胞癌，并更深入地了解这种癌症，以及通过开发索拉非尼等最有效的药物在这类癌症中实现更特异性治疗和靶向治疗所采取的步骤。为实现这一目标，我们查阅了数百篇研究论文和已发表的著作，由于篇幅限制，本文仅聚焦于肾细胞癌、肾细胞癌的治疗以及索拉非尼的临床开发等最重要的要点。本文所呈现的信息显示了人类知识的进步，即在治疗某些复杂癌症（如肾细胞癌）方面提供更有效的药物，有望在抗击这种致命疾病方面拥有更美好的未来。
